D
Dicerna Pharmaceuticals
Lexington, United States
Founded 2007
About
Developer of GalXC RNAi platform for targeted gene silencing therapeutics
Company Details
- Type
- commercial
- Employees
- 200-500
- Funding
- $500M+
- Parent Company
- Novo Nordisk
Key Products
- GalXC Platform
- Nedosiran